Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors

Renal cell carcinoma (RCC) is relatively resistant to chemotherapy and radiotherapy, whereas treatment with biologics has achieved limited success. Although monoclonal antibodies able to recognize human RCC have been identified, most induce little complement-dependent cytotoxicity or antibody-depend...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunotherapy 1996-05, Vol.19 (3), p.184-191
Hauptverfasser:	SURFUS, J. E, HANK, J. A, OOSTERWIJK, E, WELT, S, LINDSTROM, M. J, ALBERTINI, M. R, SCHILLER, J. H, SONDEL, P. M
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Neoplasm - therapeutic use Antibody-Dependent Cell Cytotoxicity - drug effects Antineoplastic agents Biological and medical sciences Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - therapy Cells, Cultured Flow Cytometry Humans Immunization, Passive - methods Immunotherapy Interleukin-2 - immunology Interleukin-2 - therapeutic use Kidney Neoplasms - immunology Kidney Neoplasms - therapy Medical sciences Mice Pharmacology. Drug treatments Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!